Implementing Treatment Algorithms for the Correction of Trauma Induced Coagulopathy

Trauma Clinical Trial

— iTACTIC  

Official title:

A Multi-centre, Prospective, Randomized Controlled Study to Compare Outcomes of Viscoelastic Haemostatic Assay (VHA)-Guided Resuscitation Versus Conventional Resuscitation Support in Haemorrhaging Trauma Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02593877
• Other study ID #: 010770
• Status: Completed
• Phase: Phase 2
• Start date: June 1, 2016
• Est. completion date: July 30, 2018

Study information

• Verified date: August 2018
• Source: Queen Mary University of London
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This trial compares the haemostatic effect of viscoelastic haemostatic assay (VHA)-guided transfusion strategy versus non-VHA guided transfusion strategy in haemorrhaging trauma patients. Half of the randomised patients will receive VHA-led management of bleeding, whilst the other half will receive massive transfusion protocol resuscitation using conventional coagulation tests.

Description:

Trauma is the most frequent cause of death in persons aged under 40, with half of these deaths resulting from uncontrolled bleeding. 1 in 4 of all severely injured and shocked patients develop a clotting abnormality termed Trauma Induced Coagulopathy (TIC) within minutes of injury, which causes blood to continue being lost from the body faster than it can be stemmed. Many more injured patients will go on to develop different types of coagulopathy at different times during the course of their treatment, either as a result of their body's ongoing response to trauma or as a consequence of their clinical care. Ultimately coagulopathic patients have increased blood transfusion requirements and suffer more adverse outcomes (e.g. multi organ failure).

Current management of coagulopathic, haemorrhaging trauma patients comprises the unguided transfusion of large volumes of red blood cells and clotting product supplements. Without rapidly available and validated diagnostics, products are delivered empirically to patients blind to the type and severity of TIC they may have or indeed even if they do not have TIC. This study will compare outcomes of viscoelastic haemostatic assay (VHA)-guided resuscitation versus conventional management of critically bleeding trauma patients. The hypothesis is that goal-directed haemostatic resuscitation of coagulopathic bleeding trauma patients will yield improved outcomes and reduced blood product demand, compared to empiric massive transfusion therapy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 412
• Est. completion date: July 30, 2018
• Est. primary completion date: July 3, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

Adult trauma patients (according to local definitions) will be enrolled if they:

• Present with hemorrhagic shock at any time from the time of injury until admission to the emergency department (where shock is defined by HR>100 b/min and/or systolic BP<90 mmHg) AND activate the local massive transfusion protocol

• Randomized within 3 hours of injury and 1 hour of admission to the emergency department

• Agreement is provided on behalf of incapacitated patients by Personal Consultee or Nominated Consultee (e.g.trauma team leader)

Exclusion Criteria:

• Any inclusion criteria are not met

Related Conditions & MeSH terms

• Blood Coagulation Disorders
• Coagulopathy
• Hemorrhage
• Hemostatic Disorders
• Trauma
• Wounds and Injuries

Intervention

Device:
• VHA algorithm
Analysis of more than 2,200 trauma subjects has enabled the definition of clinically-relevant VHA thresholds (i.e. ROTEM® and TEG® parameters) and patterns by which it is possible to rapidly identify coagulopathic patients and anticipate the need for massive transfusion. These threshold parameters have been defined and applied to the generation of an evidence-based targeted treatment algorithm (i.e. the Intervention)

Locations

Country	Name	City	State
Denmark	Copenhagen University Hospital	Copenhagen
Germany	Kliniken der Stadt Köln gGmbH	Cologne
Netherlands	Academic Medical Centre	Amsterdam
Norway	Oslo University Hospital	Oslo
United Kingdom	The Royal London Hospital	London	Greater London
United Kingdom	Queens Medical Centre	Nottingham
United Kingdom	John Radcliffe Hospital	Oxford

Sponsors (8)

Lead Sponsor	Collaborator
Queen Mary University of London	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Barts & The London NHS Trust, European Commission, Klinikum der Universität Köln, Oslo University Hospital, Oxford University Hospitals NHS Trust, Rigshospitalet, Denmark

Countries where clinical trial is conducted

Denmark,  Germany,  Netherlands,  Norway,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of subjects alive and free of massive transfusion	Proportion of subjects at 24 hours post-admission who are alive and free of massive transfusion (i.e. received 10 or more units of red blood cells within 24 hours)	24 hours
Secondary	6hr Mortality	All-cause mortality at 6-hours post admission	6 hours
Secondary	24hr Mortality	All-cause mortality at 24-hours post admission	24 hours
Secondary	28d Mortality	All-cause mortality at 28-days post admission	28-days
Secondary	90d Mortality	All-cause mortality at 90-days post admission	90-days
Secondary	Duration of coagulopathy	The time spent in coagulopathic state, as defined by Prothrombin Time / International Ratio (PTr) PTr >1.2) from Admission until the point of hemostasis (itself defined as having occurred at the end of the first hour free of red cell transfusions and the treating clinicians believe primary hemostasis has been achieved).	28-days post admission
Secondary	Severity of coagulopathy	Defined by the area under the Prothrombin Time / International Ratio (PTr) curve from Admission to the point of haemostasis (where time of hemostasis is defined as having occurred at the end of the first hour free of red cell transfusions and the treating clinicians believe primary hemostasis has been achieved).	28-days post admission
Secondary	Proportion of patients with corrected coagulopathy after first 8U RBC	Proportion of patients with corrected coagulopathy after first 8U RBC	28-days post admission
Secondary	Time to hemostasis	Time from Admission to the point of hemostasis (where time of hemostasis is defined as having occurred at the end of the first hour free of red cell transfusions and the treating clinicians believe primary hemostasis has been achieved).	28-days post admission
Secondary	Time spent in coagulopathic condition until haemostasis	Time of haemostasis is defined the period from Admission to the point as having occurred at the end of the first hour free of red cell transfusions and the treating clinicians believe primary hemostasis has been achieved. Coagulopathy defined as PTr >1.2.	28-days post admission
Secondary	6hr Blood products transfused	Total blood products (RBC, plasma, platelets alone and in total) transfused in first 6hours after admission	6 hours
Secondary	24hr Blood products transfused	Total blood products (RBC, plasma, platelets alone and in total) transfused in first 24hours after admission	24 hours
Secondary	28d Ventilator-free days	Calculated by the subtracting the number of days spent on mechanical ventilation from 28.	28 days
Secondary	28d ICU-free days	Calculated by the subtracting the number of days spent on intensive care unit from 28.	28 days
Secondary	Length of stay	Length of stay will be recorded in days, for the total number spent in ICU and in Hospital. If the patient is in the hospital at any time point during a day, this day will be considered a hospital day.	28 days
Secondary	Symptomatic thromboembolic events	Symptomatic venous thromboembolic events shall be recorded, as confirmed by radiology. Other thromboembolic events such as myocardial infarction and/or stroke shall be identified by standard clinical diagnostic investigation(s).	28 days
Secondary	Transfusion-related complications	Incidence, category and severity of acute transfusion reactions will be defined according to UK SHOT (United Kingdom Serious Hazards of Transfusion)	28-days
Secondary	Organ dysfunction	Organ dysfunction shall be measured as Sequential Organ Failure Assessment (SOFA) score from admission to day 28 or discharge	28-days
Secondary	28d/discharge QoL	Health-Related Quality of Life (HRQoL) will be measured at 28 day post admission or upon discharge if sooner	28 days
Secondary	90d QoL	Health-Related Quality of Life (HRQoL) will be measured at 90 day post admission	90 days